Baxter Income from Continuous Operations 2010-2025 | BAX
Baxter annual/quarterly income from continuous operations history and growth rate from 2010 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Baxter income from continuous operations for the quarter ending June 30, 2025 was $122M, a 139.23% decline year-over-year.
- Baxter income from continuous operations for the twelve months ending June 30, 2025 was $165M, a 139.13% increase year-over-year.
- Baxter annual income from continuous operations for 2024 was $-0.326B, a 280.11% decline from 2023.
- Baxter annual income from continuous operations for 2023 was $0.181B, a 105.81% decline from 2022.
- Baxter annual income from continuous operations for 2022 was $-3.113B, a 401.36% decline from 2021.
| Baxter Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024 | $-326 |
| 2023 | $181 |
| 2022 | $-3,113 |
| 2021 | $1,033 |
| 2020 | $1,110 |
| 2019 | $1,011 |
| 2018 | $1,552 |
| 2017 | $609 |
| 2016 | $4,966 |
| 2015 | $393 |
| 2014 | $457 |
| 2013 | $315 |
| 2012 | $2,283 |
| 2011 | $2,256 |
| 2010 | $1,427 |
| 2009 | $2,215 |
| Baxter Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2025-06-30 | $122 |
| 2025-03-31 | $64 |
| 2024-12-31 | $-82 |
| 2024-09-30 | $61 |
| 2024-06-30 | $-311 |
| 2024-03-31 | $6 |
| 2023-12-31 | $337 |
| 2023-09-30 | $37 |
| 2023-06-30 | $-193 |
| 2023-03-31 | $0 |
| 2022-12-31 | $-380 |
| 2022-09-30 | $-2,991 |
| 2022-06-30 | $185 |
| 2022-03-31 | $73 |
| 2021-12-31 | $-20 |
| 2021-09-30 | $452 |
| 2021-06-30 | $301 |
| 2021-03-31 | $300 |
| 2020-12-31 | $171 |
| 2020-09-30 | $359 |
| 2020-06-30 | $247 |
| 2020-03-31 | $333 |
| 2019-12-31 | $-19 |
| 2019-09-30 | $375 |
| 2019-06-30 | $313 |
| 2019-03-31 | $342 |
| 2018-12-31 | $302 |
| 2018-09-30 | $518 |
| 2018-06-30 | $343 |
| 2018-03-31 | $389 |
| 2017-12-31 | $-176 |
| 2017-09-30 | $248 |
| 2017-06-30 | $264 |
| 2017-03-31 | $273 |
| 2016-12-31 | $240 |
| 2016-09-30 | $127 |
| 2016-06-30 | $1,212 |
| 2016-03-31 | $3,387 |
| 2015-12-31 | $190 |
| 2015-09-30 | $2 |
| 2015-06-30 | $74 |
| 2015-03-31 | $134 |
| 2014-12-31 | $127 |
| 2014-09-30 | $175 |
| 2014-06-30 | $468 |
| 2014-03-31 | $507 |
| 2013-12-31 | $409 |
| 2013-09-30 | $528 |
| 2013-06-30 | $590 |
| 2013-03-31 | $552 |
| 2012-12-31 | $451 |
| 2012-09-30 | $583 |
| 2012-06-30 | $661 |
| 2012-03-31 | $588 |
| 2011-12-31 | $472 |
| 2011-09-30 | $578 |
| 2011-06-30 | $629 |
| 2011-03-31 | $577 |
| 2010-12-31 | $426 |
| 2010-09-30 | $524 |
| 2010-06-30 | $537 |
| 2010-03-31 | $-60 |
| 2009-12-31 | $576 |
| 2009-09-30 | $532 |
| 2009-06-30 | $589 |
| 2009-03-31 | $518 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $11.167B | $10.636B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $219.550B | 25.75 |
| Boston Scientific (BSX) | United States | $155.224B | 37.07 |
| Stryker (SYK) | United States | $149.901B | 30.56 |
| EssilorLuxottica (ESLOY) | France | $137.930B | 0.00 |
| Medtronic (MDT) | Ireland | $115.737B | 16.41 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.985B | 0.00 |
| Haleon (HLN) | United Kingdom | $42.363B | 24.18 |
| ResMed (RMD) | United States | $39.874B | 28.48 |
| Agilent Technologies (A) | United States | $32.613B | 21.26 |
| GE HealthCare Technologies (GEHC) | United States | $32.562B | 15.31 |
| Koninklijke Philips (PHG) | Netherlands | $25.229B | 16.69 |
| Terumo (TRUMY) | Japan | $25.051B | 32.54 |
| Insulet (PODD) | United States | $20.296B | 79.67 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.133B | 11.65 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.385B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.584B | 24.05 |
| Lantheus Holdings (LNTH) | United States | $4.925B | 12.42 |
| Perrigo (PRGO) | Ireland | $3.667B | 9.29 |
| Prestige Consumer Healthcare (PBH) | United States | $3.654B | 16.33 |
| Haemonetics (HAE) | United States | $3.557B | 16.20 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.202B | 21.97 |
| ICU Medical (ICUI) | United States | $3.160B | 23.31 |
| LeMaitre Vascular (LMAT) | United States | $1.836B | 41.03 |
| AtriCure (ATRC) | United States | $1.745B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.557B | 10.71 |
| Acuren (TIC) | United States | $1.347B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.251B | 28.14 |
| AdaptHealth (AHCO) | United States | $1.210B | 12.29 |
| Phibro Animal Health (PAHC) | United States | $1.074B | 13.73 |
| BioLife Solutions (BLFS) | United States | $1.017B | 0.00 |
| Neogen (NEOG) | United States | $1.010B | 16.03 |
| Curaleaf Holdings (CURLF) | Canada | $0.905B | 0.00 |
| InMode (INMD) | Israel | $0.863B | 7.99 |
| Kestra Medical Technologies (KMTS) | United States | $0.847B | 0.00 |
| Valneva SE (VALN) | France | $0.625B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.596B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.585B | 0.00 |
| Evolus (EOLS) | United States | $0.575B | 0.00 |
| Owens & Minor (OMI) | United States | $0.535B | 4.44 |
| ZimVie (ZIMV) | United States | $0.523B | 20.42 |
| CeriBell (CBLL) | United States | $0.520B | 0.00 |
| Surmodics (SRDX) | United States | $0.513B | 0.00 |
| SNDL (SNDL) | Canada | $0.452B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.374B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.330B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.300B | 11.03 |
| Quanterix (QTRX) | United States | $0.297B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.291B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.249B | 73.83 |
| Cerus (CERS) | United States | $0.245B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.241B | 20.30 |
| Omeros (OMER) | United States | $0.239B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.238B | 0.00 |
| Biote (BTMD) | United States | $0.223B | 6.26 |
| Brainsway (BWAY) | Israel | $0.221B | 58.40 |
| Sanara MedTech (SMTI) | United States | $0.215B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.211B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.205B | 0.00 |
| Exagen (XGN) | United States | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.181B | 14.87 |
| Organigram Global (OGI) | Canada | $0.180B | 0.00 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.176B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.160B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.124B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.117B | 14.45 |
| Jushi Holdings (JUSHF) | United States | $0.111B | 0.00 |
| Jin Medical (ZJYL) | China | $0.101B | 0.00 |
| MacroGenics (MGNX) | United States | $0.098B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 12.49 |
| Quipt Home Medical (QIPT) | United States | $0.096B | 0.00 |
| Safety Shot (SHOT) | United States | $0.096B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Apyx Medical (APYX) | United States | $0.072B | 0.00 |
| Veru (VERU) | United States | $0.071B | 0.00 |
| Zynex (ZYXI) | United States | $0.067B | 0.00 |
| Agape ATP (ATPC) | $0.064B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Nephros (NEPH) | United States | $0.038B | 50.71 |
| United-Guardian (UG) | United States | $0.036B | 12.38 |
| Rockwell Medical (RMTI) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |